Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:36 UTC |
---|
HMDB ID | HMDB0014415 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Isradipine |
---|
Description | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. |
---|
Structure | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3 |
---|
Synonyms | Value | Source |
---|
Dynacirc | Kegg | (+/-)-isradipine | HMDB | Isradipin | HMDB | Isrodipine | HMDB | Isradipine, (+-)-isomer | MeSH, HMDB | Isradipine, (R)-isomer | MeSH, HMDB | Isradipine, (S)-isomer | MeSH, HMDB | Lomir | MeSH, HMDB |
|
---|
Chemical Formula | C19H21N3O5 |
---|
Average Molecular Weight | 371.3871 |
---|
Monoisotopic Molecular Weight | 371.148120797 |
---|
IUPAC Name | 3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
---|
Traditional Name | isradipine |
---|
CAS Registry Number | 75695-93-1 |
---|
SMILES | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C |
---|
InChI Identifier | InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3 |
---|
InChI Key | HMJIYCCIJYRONP-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzoxadiazoles. These are organic compounds containing a benzene fused to an oxadiazole ring (a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzoxadiazoles |
---|
Sub Class | Not Available |
---|
Direct Parent | Benzoxadiazoles |
---|
Alternative Parents | |
---|
Substituents | - Benzoxadiazole
- Dihydropyridinecarboxylic acid derivative
- Dihydropyridine
- Dicarboxylic acid or derivatives
- Benzenoid
- Hydropyridine
- Azole
- Heteroaromatic compound
- Furazan
- Vinylogous amide
- Alpha,beta-unsaturated carboxylic ester
- Enoate ester
- Methyl ester
- Oxadiazole
- Amino acid or derivatives
- Carboxylic acid ester
- Secondary amine
- Azacycle
- Enamine
- Secondary aliphatic amine
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Amine
- Carbonyl group
- Organic oxygen compound
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 168 - 170 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.23 g/L | Not Available | LogP | 2.901 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Isradipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 2898.2 | Semi standard non polar | 33892256 | Isradipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 2498.3 | Standard non polar | 33892256 | Isradipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 3977.0 | Standard polar | 33892256 | Isradipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 3093.5 | Semi standard non polar | 33892256 | Isradipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 2716.0 | Standard non polar | 33892256 | Isradipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 | 3969.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Isradipine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-6059000000-e9ec514baf6b881462eb | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Isradipine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Isradipine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Isradipine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine LC-ESI-qTof , Positive-QTOF | splash10-0006-0009000000-3c8fe8c9d5e94c018299 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine LC-ESI-qTof , Positive-QTOF | splash10-03dl-2589000000-e01ef029445c948c93e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine , positive-QTOF | splash10-0006-0009000000-3c8fe8c9d5e94c018299 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine , positive-QTOF | splash10-03dl-2589000000-e01ef029445c948c93e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine 35V, Negative-QTOF | splash10-014i-1910000000-dfed2a9ad69e197388ec | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Isradipine 35V, Positive-QTOF | splash10-08gl-0093000000-018aae73f171426e9786 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 10V, Positive-QTOF | splash10-0006-0019000000-14fbaf7e209b164eca31 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 20V, Positive-QTOF | splash10-01wb-1094000000-f17e6d7b6c23adad32d6 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 40V, Positive-QTOF | splash10-001i-1192000000-f7640fb5efbe178b4418 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 10V, Negative-QTOF | splash10-00di-1029000000-a657ce350be64e5e10cf | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 20V, Negative-QTOF | splash10-05gi-3169000000-482100e723136208aa67 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 40V, Negative-QTOF | splash10-0aor-6191000000-85fa9ee77cf0b2b9a9fe | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 10V, Negative-QTOF | splash10-00di-0109000000-16c47c66d4fad17b5454 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 20V, Negative-QTOF | splash10-05fr-2019000000-e3409ae5fd7b715f6360 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 40V, Negative-QTOF | splash10-014i-0393000000-894b314cbe04d7da3127 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 10V, Positive-QTOF | splash10-03k9-0009000000-91e2afb1e32f59d7a22e | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 20V, Positive-QTOF | splash10-0h3r-0094000000-90ceb2e95c063a9a8953 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Isradipine 40V, Positive-QTOF | splash10-0fka-1292000000-d08a6d4825f5eb1d6fab | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
General References | - Fletcher H, Roberts G, Mullings A, Forrester T: An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. J Obstet Gynaecol. 1999 May;19(3):235-8. [PubMed:15512286 ]
- Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y: Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. Int J Neuropsychopharmacol. 2005 Jun;8(2):203-13. [PubMed:15850499 ]
- Ganz M, Mokabberi R, Sica DA: Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. J Clin Hypertens (Greenwich). 2005 Apr;7(4 Suppl 1):27-31. [PubMed:15858400 ]
- Hattori T, Wang PL: Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. Eur J Med Res. 2006 Mar 27;11(3):93-6. [PubMed:16751108 ]
|
---|